| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 08/11/1999 | CN1225621A Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| 08/11/1999 | CN1225620A Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors |
| 08/11/1999 | CN1225589A Purified extract of harpagophytum procumbens and/or harpagophytum zeyheri dence, process for its prodn. and its use |
| 08/11/1999 | CN1225588A Non-aqueous colonic purgative formulations |
| 08/11/1999 | CN1225585A 抗微生物组合物 The antimicrobial composition |
| 08/11/1999 | CN1225584A Tetrahydro-beta-carboline compounds |
| 08/11/1999 | CN1225360A Substituted imidazolidine derivatives, their prepn., their use and pharmaceutical prepn. comprising them |
| 08/11/1999 | CN1225263A Specific anti dizziness drug, and prescription thereof |
| 08/10/1999 | US5936123 Compounds such as 3-isopropyl-4-hydrazinobenzoic acid and its salts |
| 08/10/1999 | US5936088 Nervous system disorders |
| 08/10/1999 | US5935998 Use of all allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases |
| 08/10/1999 | US5935985 Phenoxyacetic acid derivatives |
| 08/10/1999 | US5935972 Benzofuran derivatives as tachykinin antagonists |
| 08/10/1999 | US5935931 Human apoptosis-related calcium-binding protein |
| 08/10/1999 | US5935852 The present invention relates to a family of proteins designated as cerberus, which appears to be a pioneer protein, with a 9 cysteine residue pattern, which is present in the embryo. |
| 08/10/1999 | US5935816 Isolated polynucleotide and process for producing lysyl trna synthetase using host cells and vectors; use is to screen for antibacterial compounds |
| 08/10/1999 | US5935814 G-protein coupled receptor family polypeptides, referred to as hfgan72y, altered nucleic acid seqences encoding it and recombinant materials and methods for its production; use in design of protocols and treatment of various infections |
| 08/10/1999 | US5935813 Human pancreatitis-associated protein |
| 08/09/1999 | CA2260701A1 Method of preparing substituted quinazolin-4-ones |
| 08/05/1999 | WO1999038888A2 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production |
| 08/05/1999 | WO1999038873A1 Phosphate derivatives of diaryl 1,3,4-oxadiazolone |
| 08/05/1999 | WO1999038868A1 Azolo triazines and pyrimidines |
| 08/05/1999 | WO1999038862A1 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof |
| 08/05/1999 | WO1999038854A1 Benzoate derivatives of diaryl 1,3,4-oxadiazolone |
| 08/05/1999 | WO1999038853A1 Amino acid derivatives of daryl 1,3,4-oxadiazolone |
| 08/05/1999 | WO1999038850A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 08/05/1999 | WO1999038843A1 Hydroxamic and carboxylic acid derivatives |
| 08/05/1999 | WO1999038532A2 Methods for the prevention and treatment of fibrosis and sclerosis |
| 08/05/1999 | WO1999038513A1 R-lansoprazole compositions and methods |
| 08/05/1999 | WO1999038512A1 S-lansoprazole compositions and methods |
| 08/05/1999 | WO1999038511A1 Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations |
| 08/05/1999 | WO1999038510A1 Derivatives of 1,3,4-oxadiazolone |
| 08/05/1999 | WO1999038504A1 Pharmaceutical uses of optically pure (-)-bupropion |
| 08/05/1999 | WO1999038502A1 Pharmaceutical uses of optically pure (+)-bupropion |
| 08/05/1999 | WO1999038480A2 Antiplaque oral composition and method |
| 08/05/1999 | WO1999028493A3 Method for identifying inhibitors of g-protein coupled receptor hibef51 |
| 08/05/1999 | WO1999021860B1 Phenanthroline derivatives |
| 08/05/1999 | WO1999018959A9 Pharmaceutical formulation comprising glycine as a stabilizer |
| 08/05/1999 | CA2320963A1 R-lansoprazole compositions and methods |
| 08/05/1999 | CA2320902A1 S-lansoprazole compositions and methods |
| 08/05/1999 | CA2319753A1 Antiplaque oral composition and method |
| 08/05/1999 | CA2319629A1 Amino acid derivatives of daryl 1,3,4-oxadiazolone |
| 08/05/1999 | CA2319306A1 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production |
| 08/05/1999 | CA2318960A1 Pharmaceutical uses of optically pure (+)-bupropion |
| 08/05/1999 | CA2318920A1 Pharmaceutical uses of optically pure (-)-bupropion |
| 08/05/1999 | CA2318830A1 Derivatives of 1,3,4-oxadiazolone |
| 08/05/1999 | CA2318817A1 Phosphate derivatives of diaryl 1,3,4-oxadiazolone |
| 08/05/1999 | CA2318814A1 Benzoate derivatives of diaryl 1,3,4-oxadiazolone |
| 08/05/1999 | CA2318336A1 Methods for the prevention and treatment of fibrosis and sclerosis |
| 08/04/1999 | EP0933373A1 Terpenoid lactone compounds and their production process |
| 08/04/1999 | EP0933332A1 Electrolysis of water resulting in the reduction of fat content in the human liver |
| 08/04/1999 | EP0932679A1 METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-$g(a) NUCLEIC ACIDS |
| 08/04/1999 | EP0932600A2 SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1$g(b) CONVERTING ENZYME INHIBITORS |
| 08/04/1999 | EP0932598A1 ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME |
| 08/04/1999 | EP0932410A1 Mistletoe (viscum) extracts |
| 08/04/1999 | EP0932404A1 Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| 08/04/1999 | EP0932395A1 Methods and compositions employing red yeast fermentation products |
| 08/04/1999 | EP0810989B1 Novelly substituted dtpa derivatives, metal complexes thereof, pharmaceuticals containing these complexes, diagnostic and therapeutic uses thereof and methods for preparing the complexes and pharmaceuticals |
| 08/04/1999 | EP0759027B1 Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase |
| 08/04/1999 | EP0740653B1 Hydroxamic acid derivatives as metalloproteinase inhibitors |
| 08/04/1999 | EP0665739B1 Morphogen-induced periodontal tissue regeneration |
| 08/04/1999 | CN1225085A Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| 08/04/1999 | CN1225011A Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient |
| 08/04/1999 | CN1224720A Tetracylic derivatives, process of preparation and use |
| 08/04/1999 | CN1224715A Cycloalkano-indote and againdole derivatives, process for their preparation and pharmaceutical composition containing the same |
| 08/03/1999 | US5932716 Disclosed herein are methods and compositions for identifying morphogen analogs. |
| 08/03/1999 | US5932607 Imidazole derivatives and process for preparing the same |
| 08/03/1999 | US5932598 Prodrugs of benzenesulfonamide-containing COX-2 inhibitors |
| 08/03/1999 | US5932595 Antiarthritic agent; multiple sclerosis; osteoporosis; respiratory system disorders; skin disorders; antiulcer agent |
| 08/03/1999 | US5932594 3-substituted piperidine derivative |
| 08/03/1999 | US5932581 Administering sorbitol dehydrogenase inhibitor |
| 08/03/1999 | US5932576 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| 08/03/1999 | CA2005986C Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation |
| 07/29/1999 | WO1999037682A2 Antibodies against human il-12 |
| 07/29/1999 | WO1999037668A1 Thrombin inhibitors |
| 07/29/1999 | WO1999037651A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | WO1999037639A1 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
| 07/29/1999 | WO1999037637A1 Benzamide derivatives as vasopressin antagonists |
| 07/29/1999 | WO1999037623A2 Sulphonamide derivatives for treatment of cns disorders |
| 07/29/1999 | WO1999037619A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | WO1999037617A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | WO1999037616A1 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 07/29/1999 | WO1999037604A2 Dialkyl ureas as calcitonin mimetics |
| 07/29/1999 | WO1999037326A1 Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| 07/29/1999 | WO1999037314A1 Sea cucumber carotenoid lipid fraction products and methods of use |
| 07/29/1999 | WO1999021617A3 Allosteric adenosine receptor modulators |
| 07/29/1999 | WO1999008500A3 New crystalline form of omeprazole |
| 07/29/1999 | CA2319113A1 Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| 07/29/1999 | CA2319077A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | CA2318100A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | CA2318088A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | CA2317761A1 Thrombin inhibitors |
| 07/29/1999 | CA2317740A1 Sulphonamide derivatives for treatment of cns disorders |
| 07/29/1999 | CA2284864A1 Dialkyl ureas as calcitonin mimetics |
| 07/28/1999 | EP0931788A2 Metalloprotease inhibitors |
| 07/28/1999 | EP0931543A1 Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria |
| 07/28/1999 | EP0931096A2 HT m4?, METHODS OF TREATMENT AND ASSAYS, AGONISTS AND ANTAGONISTS |
| 07/28/1999 | EP0931087A1 Novel pyranoside derivatives |
| 07/28/1999 | EP0931086A1 Tetrahydronaphthalene derivatives and their therapeutic use |
| 07/28/1999 | EP0931075A1 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |